The Saturday editions of all national dailies highlighted a Health Ministry announcement on Friday that it reached an agreement with Pfizer for the U.S. pharmaceutical company to provide enough coronavirus vaccines for 60 million people in Japan by the end of next June pending its successful development. Some 120 million doses of the vaccine will be provided since each person will require two doses. The drug firm is reportedly holding talks with the ministry about the vaccine’s approval in Japan, with Nikkei predicting that it will probably need to conduct clinical trials in Japan ahead of the vaccine’s release there. Mainichi, however, conjectured that the Health Ministry is considering granting “exceptional approval” so that Pfizer can avoid conducting time-consuming clinical testing in Japan. The GOJ is also reportedly holding talks with the U.S.’s Moderna and the UK’s AstraZeneca on the possibility of their providing Japan with their vaccines currently under development.